NEW YORK (GenomeWeb News) — Shares in Accelrys were down 5.3 percent, or $.35, at $6.21 in mid-afternoon trading after the company today posted weak fourth-quarter revenue growth and widened net loss.
As GenomeWeb News reported this morning, Accelrys said that total receipts for the three months ended Dec. 31, 2006, increased to $20.7 million from $20.4 million year over year. Losses nearly doubled to $1.1 million from $567,000 year over year.